Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule inhibitor known as LS3. It is an oxindole-based inhibitor with high selectivity for cyclin-dependent kinase 2 (CDK2) over other kinases and CDK family members. The selectivity is attributed to the presence of a sulfonyl group that interacts specifically with residues Asp86 or Lys89 in the CDK2 binding site. LS3 has been used in structural biology studies to elucidate kinase-inhibitor interactions but has not advanced into clinical development or received regulatory approval[6][4][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 3-{[(2,2-dioxido-1,3-dihydro-2-benzothien-5-yl)amino]methylene}-5-(1,3-oxazol-5-yl)-1,3-dihydro-2H-indol-2-one.